arrow
B

Brian D. Crompton

department of pediatric oncology
H指数:32
被引数:8,871

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Paediatric therapeutic development workshop on osteosarcoma

儿童骨肉瘤治疗开发研讨会

2026-08-180
OA
An international framework for clinical translation of molecular classifiers in osteosarcoma

骨肉瘤分子分类器的临床转化国际框架

2026-05-050
OAAI
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial

Tra贝替丁和低剂量伊立替康靶向EWS::FLI1在尤因肉瘤中的作用: 1/2期试验

2026-04-160
PRE
The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children’s Oncology Group

遗传祖先对儿童横纹肌肉瘤生存结局的影响:美国儿童肿瘤学会报告

2025-06-090
OA
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin
2024-04-080
OAAI
Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research
2023-09-013
OAAI
The Osteosarcoma and Leiomyosarcoma Count Me In Projects of the Cancer Moonshot funded PE-CGS Network directly engage patient participants in genomics research
2023-04-041
PRE
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA

Vigil/替莫唑胺/伊立替康治疗复发性尤因肉瘤的初步研究和循环肿瘤 (ct) DNA的评估

2023-02-138
OAAI
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma
2022-09-1722
OAAI
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children?s Oncology Group

复发性骨肉瘤患者抗对话神经节苷脂抗体dinutuximab联合gm-csf的2期研究: 儿童肿瘤学小组的报告

2022-09-0117
OAAI
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer
2022-06-2328
PRE
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group
CANCER
IF5.1
2019-07-2987
OAAI